Renal Fanconi syndrome secondary to deferasirox: Where there is smoke there is fire

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages 525-526

  Baum, Michel ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMINO ACID; AMINOGLYCOSIDE; BICARBONATE; CHLORIDE; CIDOFOVIR; CISPLATIN; CREATININE; DEFERASIROX; ELECTROLYTE; GLUCOSE; IFOSFAMIDE; IMATINIB; MERCAPTOPURINE; PARATHYROID HORMONE; PHOSPHATE; TENOFOVIR; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

APATHY; APICAL MEMBRANE; CREATININE BLOOD LEVEL; CYSTINOSIS; DISEASE PREDISPOSITION; ELECTROLYTE BLOOD LEVEL; ENZYME ACTIVITY; FANCONI RENOTUBULAR SYNDROME; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEART ARRHYTHMIA; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; HYPOVENTILATION; INTESTINAL DYSMOTILITY; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; LIPID SOLUBILITY; MALNUTRITION; METABOLIC ACIDOSIS; MUSCLE WEAKNESS; NEPHROGENIC DIABETES INSIPIDUS; NOTE; OXIDATIVE PHOSPHORYLATION; PARALYSIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; SEIZURE; SODIUM TRANSPORT; SPASTICITY; URINALYSIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT;

BENZOIC ACIDS; FANCONI SYNDROME; HUMANS; IRON CHELATING AGENTS; KIDNEY TUBULES, PROXIMAL; TRIAZOLES;

EID: 77958161115     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181ec0c4d     Document Type: Note

References (9)

1. Moe O, Seldin DW, Baum M. The Fanconi Syndrome. In: Lifton R, Somlo S, Giebisch G, et al. eds. Genetic Diseases of the Kidney Burlington. MA: Elsevier; 2009:141-160.
2. Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in B-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32:564-567.
3. Coor C, Salmon RF, Quigley R, et al. Role of adenosine triphosphate (ATP) and NaK ATPase in the inhibition of proximal tubule transport with intracellular cystine loading. J Clin Invest. 1991;87:955-961.
4. Hider RC. Charge states of deferasirox-ferric iron complexes. Am J Kidney Dis. 2010;55:614-615.
5. Oexle H, Gnaiger E, Weiss G. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta. 1999;1413:99-107.
6. Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol. 2010;85:132-134.
7. Grange S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25:2376-2378.
8. Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54:931-934.
9. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-3462.